Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MOTSNASDAQ:NVIVNASDAQ:QNRXNASDAQ:SINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMOTSMotus GI$0.00$0.00▼$0.19$1K0.924,908 shsN/ANVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsQNRXQuoin Pharmaceuticals$6.12-1.1%$7.87$5.01▼$54.95$3.60M1.3994,516 shs11,664 shsSINTSintx Technologies$2.84+9.7%$2.55$1.71▼$45.60$7.14M0.82966,069 shs52,120 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMOTSMotus GI0.00%0.00%0.00%0.00%-99.86%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%QNRXQuoin Pharmaceuticals-1.13%-2.86%+13.97%-41.71%-77.37%SINTSintx Technologies+9.65%+4.80%+49.47%-6.27%-64.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMOTSMotus GIN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals0.5184 of 5 stars0.03.00.00.02.70.00.6SINTSintx Technologies2.2919 of 5 stars3.52.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMOTSMotus GI 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ASINTSintx Technologies 3.00Buy$30.00956.34% UpsideCurrent Analyst Ratings BreakdownLatest SINT, MOTS, QNRX, and NVIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$70.00 ➝ $30.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMOTSMotus GI$319K0.00N/AN/A$1.74 per share0.00NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ASINTSintx Technologies$1.25M5.73N/AN/A$329.74 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMOTSMotus GI-$12.87M-$15.64N/AN/AN/AN/AN/AN/AN/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/AQNRXQuoin Pharmaceuticals-$8.69M-$81.12N/AN/AN/AN/A-125.60%-64.77%5/13/2025 (Estimated)SINTSintx Technologies-$8.26M-$50.56N/A∞N/A-358.79%-140.68%-78.29%N/ALatest SINT, MOTS, QNRX, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$0.11N/AN/AN/AN/AN/A3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMOTSMotus GIN/AN/AN/ANVIVInVivo TherapeuticsN/A14.3014.30QNRXQuoin PharmaceuticalsN/A3.023.02SINTSintx TechnologiesN/A3.042.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%QNRXQuoin Pharmaceuticals8.63%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipMOTSMotus GI0.34%NVIVInVivo Therapeutics2.45%QNRXQuoin Pharmaceuticals3.70%SINTSintx Technologies0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMOTSMotus GI305.77 million5.75 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableSINTSintx Technologies402.52 million1.34 millionNot OptionableSINT, MOTS, QNRX, and NVIV HeadlinesRecent News About These CompaniesSintx Technologies, Inc. (NASDAQ:SINT) Insider Gregg R. Honigblum Buys 10,000 SharesMay 1, 2025 | insidertrades.comSintx Technologies Appoints Five New Board DirectorsApril 8, 2025 | tipranks.comSintx Technologies announces changes to board, Chairman Bal to retireApril 5, 2025 | markets.businessinsider.comSINTX Technologies Announces Strategic Changes to Board of DirectorsApril 3, 2025 | markets.businessinsider.comSINTX: Peer-reviewed Study Shows Biomechanical Advantages Of Silicon Nitride In ACDF ProceduresMarch 21, 2025 | nasdaq.comMaxim Group Reaffirms Their Hold Rating on Sintx Technologies (SINT)March 21, 2025 | markets.businessinsider.comSintx Technologies announces publication of study on silicon nitride in ACDFMarch 20, 2025 | markets.businessinsider.comSintx Technologies files to sell 3.01M shares of common stock for holdersMarch 20, 2025 | markets.businessinsider.comSINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine FusionMarch 19, 2025 | markets.businessinsider.comSintx Technologies Announces Board Chairman TransitionMarch 17, 2025 | markets.businessinsider.com3SINT : Why SINTX Technologies Stock Is Down 21%February 26, 2025 | benzinga.comSintx Technologies prices 1.45M shares at $3.45 in private placementFebruary 26, 2025 | markets.businessinsider.comSINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq RulesFebruary 26, 2025 | globenewswire.comSintx Technologies sells Technology Assessment and Transfer to TethonFebruary 21, 2025 | markets.businessinsider.comSINTX Technologies divests technology assessment and transfer subsidiaryFebruary 20, 2025 | msn.comSINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device MarketFebruary 20, 2025 | globenewswire.comThis Healthcare Stock Rose Sharply On USPTO IssuanceFebruary 19, 2025 | msn.comThis Penny Stock Is Surging on Patent News. Analysts Think It Gain 1,300% From Here.February 19, 2025 | msn.comSintx Technologies awarded patent on silicon nitride material by USPTOFebruary 19, 2025 | markets.businessinsider.comSINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic BiomaterialFebruary 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, MOTS, QNRX, and NVIV Company DescriptionsMotus GI NASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Quoin Pharmaceuticals NASDAQ:QNRX$6.12 -0.07 (-1.13%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$6.40 +0.28 (+4.58%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sintx Technologies NASDAQ:SINT$2.84 +0.25 (+9.65%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$2.97 +0.13 (+4.44%) As of 05/12/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
